Elektra Health Prescribing Data and Outcomes Signals: What Patients Should Know

What Is Elektra Health and How Does It Work?

Elektra Health is a direct-to-patient telehealth company founded to address the care gap in menopause medicine. The platform connects patients with clinicians who specialize in perimenopause and menopause and offers both synchronous video visits and asynchronous messaging. Billing runs through insurance for eligible members or through a cash membership model.

Business Model and Clinical Scope

Elektra is not a compounding pharmacy and does not manufacture its own drug products. Clinicians on the platform write prescriptions for FDA-approved hormone therapy products, including estradiol patches, gels, and sprays, as well as oral progesterone (micronized progesterone, marketed as Prometrium). They also prescribe non-hormonal options such as the SNRI venlafaxine and, for patients who qualify, the recently approved neurokinin-3 antagonist fezolinetant (Veozah), which the FDA cleared in May 2023 specifically for moderate-to-severe vasomotor symptoms [1].

Patients complete a structured intake questionnaire covering symptom burden, cardiovascular history, personal and family cancer history, and prior hormone use. That intake data theoretically allows for risk stratification before prescribing, though Elektra has not published the specific algorithm or thresholds it uses internally.

Practitioner Credentials

Elektra lists physicians and nurse practitioners on its clinical team. Board certification details and state licensure are not uniformly disclosed on the public-facing website for every clinician, which is a transparency gap patients should probe before their first visit. You can verify any prescriber's license independently through your state medical or nursing board's online lookup tool in under five minutes.

Is Elektra Health Legitimate? Regulatory and Accreditation Signals

Short answer: yes, with caveats. Elektra Health operates legally as a telehealth platform and prescribes only FDA-approved medications through licensed clinicians. No FDA warning letter, FTC enforcement action, or state medical board public order names Elektra Health as of the publication date of this article.

FDA and FTC Standing

The FDA's warning letter database (accessdata.fda.gov) does not contain any public enforcement action against Elektra Health. The FTC's health claims enforcement actions, available at ftc.gov, do not list the company either. That absence is a baseline legitimacy signal, not a quality endorsement.

The FDA approved fezolinetant (Veozah, Astellas) based on the SKYLIGHT 1 and SKYLIGHT 2 trials. In SKYLIGHT 2 (N=501), fezolinetant 45 mg reduced mean daily vasomotor symptom frequency by 64% at week 52 compared with 45% for placebo (P<0.001) [2]. Any platform prescribing this drug appropriately is working within the evidence base.

LegitScript and Pharmacy Risk

LegitScript, which monitors online pharmacies and telehealth platforms for regulatory compliance, has not flagged Elektra Health on its public risk database. Platforms that direct patients to rogue or unaccredited pharmacies commonly appear in LegitScript's "not recommended" or "rogue" tiers. Elektra routes patients to licensed retail and mail-order pharmacies, consistent with standard telehealth practice.

BBB Profile and Complaint Volume

Elektra Health has a profile on the Better Business Bureau website. As of mid-2025, the number of formal complaints filed against the company is low in absolute terms and proportionally small relative to its membership base, though the exact figure fluctuates. Common complaint themes across telehealth companies in this category include billing disputes, prescription delays, and difficulty reaching clinical staff. Patients encountering these issues at any telehealth platform should document all communications in writing and escalate first through the platform's patient advocate channel before filing a BBB or state insurance commissioner complaint.

Prescribing Patterns: What Elektra Clinicians Actually Recommend

Elektra has not published a prescribing data report, formulary breakdown, or outcomes registry in any peer-reviewed journal or on its public website as of this writing. That is a transparency limitation shared by most telehealth brands in this space. What follows draws on the public clinical content Elektra produces (blog posts, webinars, clinical protocols described in press materials) and on the established evidence base for the treatments they are known to offer.

Hormone Therapy: The Evidence Foundation

The North American Menopause Society (NAMS) 2022 position statement states: "For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and prevention of bone loss." [3] Elektra's public clinical content aligns with this framing, emphasizing individualized risk-benefit discussions rather than blanket prescribing.

Transdermal estradiol is generally preferred for patients with elevated cardiovascular or thromboembolic risk because it bypasses first-pass hepatic metabolism, avoiding the increase in clotting factors associated with oral estrogens. The ESTHER study (N=881) found that oral estrogen-only therapy was associated with a four-fold increase in venous thromboembolism risk compared with non-users, whereas transdermal estrogen was not associated with a significantly elevated risk (OR 0.9, 95% CI 0.5-1.6) [4]. Elektra's educational materials reference transdermal routes, which suggests their prescribing defaults toward evidence-consistent choices, though no audit confirms this at scale.

Non-Hormonal Options

For patients who cannot or prefer not to use estrogen, the evidence supports several alternatives. Venlafaxine 75 mg daily reduced hot-flash frequency by approximately 61% in a randomized trial published in the Journal of Clinical Oncology [5]. Gabapentin and clonidine carry weaker evidence and more side-effect burden. The selective estrogen receptor modulator ospemifene (Osphena) addresses genitourinary syndrome of menopause without systemic estrogen exposure and carries FDA approval for that indication [6].

Whether Elektra clinicians consistently discuss all approved non-hormonal options during a visit depends on individual clinician training and visit length. Asynchronous messaging platforms structurally limit the depth of shared decision-making possible in a face-to-face or video appointment.

Compounding: What Elektra Does Not Do

Elektra does not appear to prescribe bio-identical hormone compounding products (custom-compounded BHRT pellets, troches, or transdermal creams from 503A compounding pharmacies) based on available public information. NAMS, the Endocrine Society, and ACOG have all published positions noting that compounded hormone products lack the safety and efficacy testing of FDA-approved products and should not be used when an approved alternative exists [7]. Sticking to FDA-approved products is a meaningful quality signal.

Outcomes Signals: What the Data (and Absence of Data) Tells Us

No peer-reviewed outcomes study specific to Elektra Health's patient population exists in PubMed or ClinicalTrials.gov as of July 2025. That is not unusual for a private telehealth company, but it matters when evaluating whether platform-specific care translates to population-level benefit.

Applying Trial Data to Telehealth Platforms

The MENQOL (Menopause-Specific Quality of Life Questionnaire) and the Greene Climacteric Scale are validated instruments for tracking symptom burden over time. Neither Elektra's website nor any press release references these tools as part of a formal quality measurement program. Platforms that collect structured, validated outcome data and publish it, even in aggregate, earn higher clinical credibility than those that rely solely on testimonials.

A HealthRX-proposed framework for evaluating any menopause telehealth brand on outcomes rigor uses four criteria: (1) validated symptom tracking instruments used at intake and follow-up, (2) prescription data reviewed against NAMS guidelines at a population level, (3) adverse event reporting pathway that is patient-accessible, and (4) third-party audit or accreditation. Elektra publicly meets criterion (3) through standard telehealth complaint channels, but criteria (1), (2), and (4) remain unverified from public sources.

What Patient Reviews Suggest

Aggregated patient reviews on platforms such as Trustpilot and Google Reviews (not primary medical sources, but signal-bearing) point to generally positive experiences with access and symptom relief. Negative reviews cluster around billing complexity and wait times for appointments. Neither category of feedback tells us whether clinicians are applying guideline-concordant prescribing. Symptom relief is necessary but not sufficient evidence of quality care; a clinician prescribing inappropriate doses or skipping contraindication screening could produce short-term relief while creating longer-term risk.

The WHI Re-Analysis Context

Much of the fear around menopausal hormone therapy traces back to the original Women's Health Initiative publications in 2002 and 2004. Re-analyses and subsequent long-term data have substantially revised that picture. The WHI observational follow-up published in JAMA in 2017 (N=27,347 women, 18-year follow-up) found that women who initiated hormone therapy near menopause had no significant increase in all-cause mortality [8]. Patients who received care from Elektra between, say, 2019 and 2023, during a period when hormone therapy prescribing was still suppressed by lingering WHI anxiety, may have benefited from earlier access to evidence-aligned treatment. But this is inference, not measurement.

Elektra Health Complaints: Patterns and Patient Protections

Complaints about Elektra Health, drawn from the BBB, app store reviews, and health forums, fall into three categories.

Billing and Insurance Disputes

Insurance billing for telehealth menopause care is genuinely complex. ICD-10 codes for menopausal symptoms (N95.1 for menopausal and female climacteric states, for example) may or may not be covered depending on the patient's plan tier. Patients report receiving unexpected out-of-pocket charges after being told their insurance was accepted. This is a billing process failure, not a clinical safety failure, but it erodes trust and may cause patients to abandon care before completing a treatment trial.

Before your first Elektra visit, obtain a written pre-authorization reference number from your insurer for a telehealth evaluation visit and ask Elektra's billing team to confirm the specific CPT codes they plan to use.

Prescription Delays and Pharmacy Coordination

Some patients report delays between a completed visit and pharmacy receipt of a prescription, sometimes extending four to seven days. For patients in acute vasomotor symptom distress, a week's delay is clinically meaningful. Ask the clinician at the end of your visit to confirm the pharmacy transmission method and expected fill timeline.

Access to Clinical Staff

A recurring complaint is difficulty reaching a clinician for follow-up questions after a visit. Asynchronous messaging systems work well for low-urgency questions but fail patients who need rapid clarification on a new side effect or drug interaction. Patients with complex medical histories should confirm response-time commitments before enrolling.

How Elektra Compares on Prescribing Standards

NAMS published a comprehensive position statement in 2022, and the Menopause Society (formerly NAMS) updated guidance in 2023 that affirms: "Hormone therapy remains the most effective treatment for vasomotor symptoms and the GSM and has been shown to prevent bone loss and fracture." [3] A clinician or platform operating in alignment with that guidance should be able to:

• Identify contraindications (undiagnosed vaginal bleeding, active breast cancer, history of VTE without anticoagulation, active liver disease).
• Route higher-cardiovascular-risk patients toward transdermal rather than oral estradiol.
• Prescribe micronized progesterone (oral, 100-200 mg nightly) for uterine protection rather than synthetic progestins when possible, given the KEEPS and E3N cohort data suggesting a more favorable breast risk profile.
• Reassess therapy at six months and annually thereafter.

Whether Elektra's clinicians consistently execute all four steps cannot be confirmed from public data. The platform's educational materials suggest awareness of these standards, but structural quality assurance data is not public.

The E3N cohort study (N=80,377 French women) found that combined estrogen plus synthetic progestogen was associated with a significantly higher breast cancer risk (RR 1.69, 95% CI 1.50-1.91) compared with estrogen plus micronized progesterone (RR 1.00, 95% CI 0.83-1.22) [9]. Progesterone choice is not a minor clinical detail. It is one of the clearest quality markers separating guideline-concordant prescribing from outdated practice.

What to Ask Elektra Health Before You Prescribe

Patients evaluating Elektra (or any menopause telehealth platform) should ask five specific questions at or before the first clinical encounter:

1. What form of estradiol will you prescribe and why (patch, gel, pill), given my cardiovascular risk profile?
2. If I have a uterus, which progestogen will you use and why?
3. What symptom tracking tool will you use to measure my response at 8-12 weeks?
4. How quickly can I reach a clinician if I have a side effect or question between scheduled visits?
5. Does your platform prescribe compounded hormone products, and if so, under what circumstances?

A clinician who cannot answer questions 1 and 2 with specific pharmacologic reasoning has not completed an individualized risk-benefit assessment. That is a red flag regardless of which telehealth platform you use.